Damon DeSantis
CIK: 0001889279
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Sep 15, 2026CELH
Celsius Holdings, Inc.
Purchase(P)Direct16K shares at avg. $27.95$447K - Sep 14, 2026CELH
Celsius Holdings, Inc.
Purchase(P)Direct20K shares at avg. $27.65$553K - Jun 24, 2026INBP
INTEGRATED BIOPHARMA INC
Award(A)DirectStock Option (Right to Buy)
50K shares- - Apr 15, 2026INBP
INTEGRATED BIOPHARMA INC
Gift(G)Indirect9M shares- - Apr 15, 2026INBP
INTEGRATED BIOPHARMA INC
Gift(G)Indirect2.2M shares- - Mar 24, 2026INBP
INTEGRATED BIOPHARMA INC
Gift(G)Indirect7.4K shares- - Mar 24, 2026INBP
INTEGRATED BIOPHARMA INC
Gift(G)Indirect1.4M shares- - Feb 27, 2026CELH
Celsius Holdings, Inc.
Award(A)Direct2.6K shares- - Jun 18, 2025INBP
INTEGRATED BIOPHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares- - Mar 1, 2025CELH
Celsius Holdings, Inc.
Award(A)Direct4.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 |  CELH Celsius Holdings, Inc. | Purchase(P) | 16,000 | $27.95 | $447,200 | Direct |
| Sep 14, 2026 | CELH Celsius Holdings, Inc. | Purchase(P) | 20,000 | $27.65 | $553,000 | Direct |
| Jun 24, 2026 |  INBP INTEGRATED BIOPHARMA INC | Award(A) Stock Option (Right to Buy) | 50,000 | - | - | Direct |
| Apr 15, 2026 | INBP INTEGRATED BIOPHARMA INC | Gift(G) | 8,966,547 | - | $0 | Indirect |
| Apr 15, 2026 | INBP INTEGRATED BIOPHARMA INC | Gift(G) | 2,235,417 | - | $0 | Indirect |
| Mar 24, 2026 | INBP INTEGRATED BIOPHARMA INC | Gift(G) | 7,392 | - | $0 | Indirect |
| Mar 24, 2026 | INBP INTEGRATED BIOPHARMA INC | Gift(G) | 1,356,293 | - | $0 | Indirect |
| Feb 27, 2026 | CELH Celsius Holdings, Inc. | Award(A) | 2,611 | - | $0 | Direct |
| Jun 18, 2025 | INBP INTEGRATED BIOPHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Mar 1, 2025 | CELH Celsius Holdings, Inc. | Award(A) | 4,865 | - | - | Direct |
1-10 of 10 transactions
About DeSantis Damon
DeSantis Damon (SEC CIK 0001889279) files insider reports with the SEC as Director of Celsius Holdings, Inc. (CELH) and Director of INTEGRATED BIOPHARMA INC (INBP).
Signal8 holds 7 ownership filings by DeSantis Damon, all Form 4s, filed between Mar 4, 2025 and Sep 15, 2026. Those filings report 10 transactions, from Mar 1, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DeSantis Damon's filings is in BOCA RATON, FL.
Recent filings by DeSantis Damon
- Sep 15, 2026: Open-market purchase of CELH shares (Form 4, code P).
- Sep 14, 2026: Open-market purchase of CELH shares (Form 4, code P).
- Jun 24, 2026: Grant or award of INBP derivative securities (Form 4, code A).
- Apr 15, 2026: Gifts of INBP shares (2 lines, Form 4, code G).
- Mar 24, 2026: Gifts of INBP shares (2 lines, Form 4, code G).
Other insiders filing for Celsius Holdings, Inc. (CELH)
- Kravitz Hal, Director
- Fieldly John, Chief Executive Officer
- Previn Fletcher F, Director
- Milmoe William H., Officer
- DeSantis Deborah, Officer
- DeSantis Dean, Officer